July 2026– date –
-
EMD Serono’s Investigational Enpatoran Granted FDA Breakthrough Therapy Designation for Active Cutaneous Lupus
Lupus Foundation of America USA Overview EMD Serono's investigational drug enpatoran has received Breakthrough Therapy Designation from the U.S. FDA for the treatment of systemic lupus erythematosus (SLE) with active cutaneous manifestat... -
Obesity Treatment Advances: Foundayo and Oral Wegovy Lead Oral GLP-1 Market, Retatrutide Shows Significant Weight Loss in Phase II
GoodRx Health USA Overview The obesity therapeutics market is rapidly evolving, with Foundayo (orforglipron) and oral Wegovy driving the oral GLP-1 segment. Foundayo, FDA-approved on April 1, 2026, offers the novel advantage of being tak... -
Breaking the Blood-Brain Barrier: Nanoparticles Chart New Course for Neurodegenerative Therapies
Dove Medical Press New Zealand Overview The blood-brain barrier (BBB) prevents over 98% of small-molecule drugs and nearly all biologics from entering the brain, posing a major challenge for neurological therapies. Nanoparticles (NPs) of... -
UT MD Anderson Tackles Brain Tumor Therapy by Advancing Multiple Blood-Brain Barrier Penetration Strategies
UT MD Anderson Cancer Center USA Overview Researchers at UT MD Anderson Cancer Center are aggressively pursuing multiple research strategies to overcome the blood-brain barrier (BBB), a formidable challenge in brain tumor treatment. Whil... -
Boehringer Ingelheim’s First-in-Class Obesity Drug BI 3034701 Enters Phase II, Triggers €10M Milestone Payment to Gubra
Boehringer Ingelheim Germany Overview Boehringer Ingelheim has initiated a Phase II clinical trial for BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist for patients with obesity and overweight. This investiga... -
From Noise to Novel 3D Molecules: Diffusion Models Transform Drug Design AI
Google Cloud Vertex AI Search USA Overview Diffusion models, a breakthrough AI methodology successful in image generation, are now being applied to molecular structure generation for drug design. These models generate new molecules by pr... -
LNP Innovation Revolutionizes RNA Delivery: Advancing Tissue-Specific Targeting and Immunoprofile Optimization
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) have established themselves as the most clinically validated and advanced platform for RNA drug delivery. LNPs critically protect nucleic acids from enzymatic degradation, facil... -
Large Models Reshape Chemistry: Generative AI Drives Novel Molecular Design in Drug Discovery
Google Cloud Vertex AI Search USA Overview Generative AI is fundamentally transforming drug chemistry by creating novel molecular structures rather than merely screening existing ones. These large machine learning models learn patterns o... -
Generative AI Accelerates Drug Discovery: Reshaping Molecular Design and Translational Decision-Making
Google Cloud Vertex AI Search USA Overview Generative AI is poised to revolutionize the entire drug discovery pipeline, from initial molecular design and chemical space exploration to ADMET prediction and crucial translational decision-m... -
Lonza and Engitix Ink ADC License Deal for ECM-Targeted Cancer, Fibrosis Therapies
GEN (Genetic Engineering & Biotechnology News) Switzerland Overview Lonza and Engitix Ltd. have signed a licensing agreement for an Antibody-Drug Conjugate (ADC) technology platform, targeting cancer and fibrosis therapies focused on the...
